Stroke patients treated intravenously with loberamisal, a novel neuroprotective medication, daily for 10 days and starting ...

Late-Breaking Science Abstract LB 032 - In a phase III clinical trial in China, stroke patients treated intravenously with loberamisal, a novel neuroprotective medication, daily for 10 days starting ...

NEW ORLEANS -- Loberamisal improved functional outcomes after acute ischemic stroke in a placebo-controlled phase III trial, ...

With the study adding to a mix of conflicting trial results, it’s not yet time to update guidelines, Shyam Prabhakaran says.

In a phase III clinical trial in China, stroke patients treated intravenously with loberamisal, a novel neuroprotective ...

A large US registry-based study shows that longer door-in-door-out (DIDO) times at the referring hospital are strongly ...

Results from the CHOICE-2 trial show a 15% absolute increase in excellent functional outcomes with intra-arterial alteplase ...

A new predictive tool may help identify patients at risk for poststroke dementia, potentially accelerating research and ...

Though recombinant factor VIIa didn’t improve outcomes overall, treating very early and in those with a spot sign on CT may ...

For patients after ischemic stroke, extremely low-frequency, low-intensity electromagnetic field brain stimulation reduces disability.

Chamorro argued that the apparent difference in mortality likely reflects an "extremely low" event rate among control ...

Alteplase, a “clot-buster” medication used to treat ischemic stroke, acute myocardial infarctions, and acute pulmonary ...